Physician profile
David E Schmidt
NPI 1356301220
$34,558.07
in general payments reported to CMS, 2019-2025
35 companies · $663 in 2025
The $663 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $1,709 · 2021: $7,892 · 2022: $6,334 · 2023: $1,049 · 2024: $1,680 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,297 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,296.87 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27,353.16 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,077.67 | 2019-2025 | |
| Amgen INC. | $1,007.41 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $725.79 | 2019-2024 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $499.54 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $377.19 | 2019-2025 | |
| Amarin Pharma, INC. | $337.83 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $334.99 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $316.89 | 2019-2025 | Wainua, Andexxa, Farxiga |
| Abbott Laboratories | $281.56 | 2019-2025 | Aveir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $219.77 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.05 | 2021-2025 | Jardiance |
| Medtronic, INC. | $149.43 | 2021-2024 | Corevalve Evolut R |
| Abiomed | $139.27 | 2019-2023 | Impella |
| Lexicon Pharmaceuticals, INC. | $135.93 | 2024 | Inpefa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $127.21 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $123.82 | 2019 | |
| Medtronic Vascular, INC. | $120.62 | 2019-2020 | |
| Gilead Sciences, INC. | $119.79 | 2019 | |
| Novo Nordisk INC | $111.85 | 2021-2024 | Ozempic, Rybelsus |
| Atricure, INC. | $111.49 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $101.44 | 2022-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $93.62 | 2021-2024 | Onpattro |
| Boston Scientific Corporation | $92.84 | 2019-2025 | Bodyguardian |
| Regeneron Healthcare Solutions, INC. | $74.24 | 2019-2024 | Evkeeza |
| Lundbeck LLC | $63.81 | 2019-2020 | |
| Bridgebio Pharma, INC. | $50.17 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $47.88 | 2020-2025 | |
| Bardy Diagnostics, INC. | $41.85 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $36.43 | 2021 | |
| Heartflow, INC. | $34.21 | 2023-2025 | Ffrct |
| Cleerly, INC. | $30.44 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Edwards Lifesciences Corporation | $26.49 | 2022 | |
| Angiodynamics, INC. | $19.54 | 2020 | |
| Scpharmaceuticals INC. | $17.85 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.